ABSTRACT
28
Manuscript M a n u s c r i p t 2 TCID 50 /mL of an Italian field isolate of BTV serotype 4. Three additional calves were included in 29 the study and used as sentinels to confirm that no BTV was circulating locally.
30
At the time of the challenge, only one vaccinated animal did not have neutralizing antibodies
31
against BTV-4, while the remaining 15 showed titres of at least 1:10 for either BTV-2 or BTV-4.
32
However, the BTV-2 component of the inactivated vaccine elicited a stronger immune response
33
in terms of both the number of virus neutralization (VN) positive animals and antibody titres.
34
After challenge, no animal showed signs of disease. 
90
Both BTV-2 and BTV-4 vaccine strains originated from France (Corsica).
91
Sixteen cattle were vaccinated with 1 mL of the vaccine on day 0 and on day 28. The vaccine 
108
Thirty-five 4 month-old calves that were free of respiratory, digestive, umbilical and osteo-109 articular disease were included in the study. All animals originated from BTV-free herd, located 110 in a BTV-free area (France) and tested negative for BTV-antibodies (c-ELISA) before entering 111 the study.
112
Thirty-two calves were randomly allocated into 2 groups of 16 animals each. One group was 113 vaccinated and the second group was left unvaccinated and used as control.
114
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117
Thus, animals were allocated to four groups : (1) "Controls BTV-2", (2) "Controls BTV-4", (3)
118
"Vaccinates BTV-2", (4) "Vaccinates BTV-4".
119
The three remaining animals were kept as environmental controls (not vaccinated nor 120 challenged), and used as sentinels to confirm that no BTV was circulating locally. 
125
Prior to challenge, all bovines were blood sampled for detection of viraemia by jugular 126 puncture with ethylene-diaminetetra-acetic acid (EDTA) tubes. After challenge, blood samples
127
were taken 3 times a week for 42 days (day 65 -> day 107).
128
To exclude viral circulation in the stable, the environmental control animals were bled once a also assessed by using the RT-PCR which amplifies a portion of S5 as described by Katz et al.
137
(1993). Its sensitivity for BTV-2 and BTV-4 of either field or vaccine origin was evaluated by 138 testing viral suspensions whose titer was previously determined.
139
On day 7, in the absence of cytopathic effect (CPE), cultures were scraped, centrifuged, and 
160
Differences between the neutralising titres against BTV-2 and 4 per sampling day in the 161 vaccinated group after immunisation, were analysed using the non-parametric Wilcoxon test
162
for paired groups (Siegel and Castellani, 1998) , while differences between BTV-2 and 4
163
viraemic titres per sampling day in the control groups were analysed using the non-parametric
164
Mann-Whitney test for independent groups. The probability of the various possible sensitivity
165
values of the C-ELISA in the vaccinated animals were estimated through a Bayesian approach 166 using the Beta (s+1, n-s+1) distribution (Sivia, 1996) where s is the total number of positives
167
and n is the total number of tested animals. Different Beta distributions were calculated on the 
196
For BTV-2, 28 days after first vaccination, 13 had sero-converted, but at low titres. By day 42, M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t 
